je.st
news
Actavis Beats Q3 Views As Buyout Talk Swirls
2014-11-06 05:57:54| Biotech - Topix.net
Generic and specialty drug giant Actavis beat Wall Street's third-quarter estimates and raised its guidance early Wednesday, sending the stock to a new high of 254.41 before closing up 1.1% at 247.91. ' earnings, excluding one-time items, rose 53% over the year-earlier quarter to $3.19 a share, beating analysts' consensus by 9 cents, according to Thomson Reuters.
Tags: views
talk
beats
buyout
Category:Biotechnology and Pharmaceuticals